Producción científica por año
Producción científica por año
Huella digital
Profundizar en los temas de investigación en los que Eric J Lawitz está activo. Estas etiquetas de temas provienen de las obras de esta persona. Juntos, forma una huella digital única.
- 1 Perfiles similares
Colaboraciones y áreas de investigación principales de los últimos cinco años
Colaboración externa reciente a nivel de país/territorio. Para consultar los detalles, haga clic en los puntos o
-
Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors' Perspective
Younossi, Z. M., Razavi, H., Sherman, M., Allen, A. M., Anstee, Q. M., Cusi, K., Friedman, S. L., Lawitz, E., Lazarus, J. V., Schuppan, D., Romero-Gómez, M., Schattenberg, J. M., Vos, M. B., Wong, V. W. S., Ratziu, V., Hompesch, M., Sanyal, A. J. & Loomba, R., 2025, (Accepted/In press) En: Alimentary Pharmacology and Therapeutics.Producción científica: Article › revisión exhaustiva
-
Effect of Target-Mediated Disposition on Iptacopan Clinical Pharmacokinetics in Participants with Normal or Impaired Hepatic Function
Burmeister Getz, E., Stein, R. R., Fink, M., Kulmatycki, K., Baltcheva, I., Weis, W., Shah, B., Lawitz, E. & Schmouder, R., 2025, (Accepted/In press) En: Clinical Pharmacology and Therapeutics.Producción científica: Article › revisión exhaustiva
Acceso abierto -
A Phase 1, Single-Dose Study to Evaluate the Pharmacokinetics and Safety of Bepirovirsen in Adults with Hepatic Impairment and Healthy Participants (B-Assured)
Noormohamed, N., Lukic, T., Marbury, T. C., Lawitz, E. J., Prescott, H., Magee, M., Nader, A. & Han, K., oct 2024, En: Clinical Pharmacology in Drug Development. 13, 10, p. 1088-1097 10 p.Producción científica: Article › revisión exhaustiva
Acceso abierto -
A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
for the 1404-0043 Trial Investigators, jul 25 2024, En: New England Journal of Medicine. 391, 4, p. 311-319 9 p.Producción científica: Article › revisión exhaustiva
Acceso abierto94 Citas (Scopus) -
A randomized, double-blind, placebo-controlled trial of aldafermin in patients with NASH and compensated cirrhosis
Rinella, M. E., Lieu, H. D., Kowdley, K. V., Goodman, Z. D., Alkhouri, N., Lawitz, E., Ratziu, V., Abdelmalek, M. F., Wong, V. W. S., Younes, Z. H., Sheikh, A. M., Brannan, D., Freilich, B., Membreno, F., Sinclair, M., Melchor-Khan, L., Sanyal, A. J., Ling, L. & Harrison, S. A., mar 2024, En: Hepatology. 79, 3, p. 674-689 16 p.Producción científica: Article › revisión exhaustiva
Acceso abierto35 Citas (Scopus)
Conjuntos de datos
-
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
Zoulim, F. (Creator), Moreno, C. (Creator), Lee, S. S. (Creator), Buggisch, P. (Creator), Horban, A. (Creator), Lawitz, E. (Creator), Corbett, C. (Creator), Lenz, O. (Creator), Fevery, B. (Creator), Verbinnen, T. (Creator), Shukla, U. (Creator) & Jessner, W. (Creator), Figshare, 2018
DOI: 10.6084/m9.figshare.c.3990051.v1, https://springernature.figshare.com/collections/A_3-year_follow-up_study_after_treatment_with_simeprevir_in_combination_with_pegylated_interferon-_and_ribavirin_for_chronic_hepatitis_C_virus_infection/3990051/1
Dataset
-
A 3-year follow-up study after treatment with simeprevir in combination with pegylated interferon-α and ribavirin for chronic hepatitis C virus infection
Zoulim, F. (Creator), Moreno, C. (Creator), Lee, S. S. (Creator), Buggisch, P. (Creator), Horban, A. (Creator), Lawitz, E. (Creator), Corbett, C. (Creator), Lenz, O. (Creator), Fevery, B. (Creator), Verbinnen, T. (Creator), Shukla, U. (Creator) & Jessner, W. (Creator), Figshare, 2018
DOI: 10.6084/m9.figshare.c.3990051, https://figshare.com/collections/A_3-year_follow-up_study_after_treatment_with_simeprevir_in_combination_with_pegylated_interferon-_and_ribavirin_for_chronic_hepatitis_C_virus_infection/3990051
Dataset
-
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Feld, J. J. (Creator), Lawitz, E. (Creator), Nguyen, T. (Creator), Lalezari, J. (Creator), Hassanein, T. (Creator), Martin, P. (Creator), Han, S.-H. (Creator), Dieterich, D. (Creator), Giard, J.-M. (Creator), De La Rosa, G. (Creator), Ahmad, A. (Creator), Luo, E. (Creator), Conery, A. L. (Creator) & Adda, N. (Creator), SAGE Journals, 2022
DOI: 10.25384/sage.c.6301764, https://sage.figshare.com/collections/EDP-514_in_healthy_subjects_and_nucleos_t_ide_reverse_transcriptase_inhibitor-suppressed_patients_with_chronic_hepatitis_B/6301764
Dataset
-
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Feld, J. J. (Creator), Lawitz, E. (Creator), Nguyen, T. (Creator), Lalezari, J. (Creator), Hassanein, T. (Creator), Martin, P. (Creator), Han, S.-H. (Creator), Dieterich, D. (Creator), Giard, J.-M. (Creator), De La Rosa, G. (Creator), Ahmad, A. (Creator), Luo, E. (Creator), Conery, A. L. (Creator) & Adda, N. (Creator), SAGE Journals, 2022
DOI: 10.25384/sage.c.6301764.v1, https://sage.figshare.com/collections/EDP-514_in_healthy_subjects_and_nucleos_t_ide_reverse_transcriptase_inhibitor-suppressed_patients_with_chronic_hepatitis_B/6301764/1
Dataset
-
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B
Feld, J. J. (Creator), Lawitz, E. (Creator), Nguyen, T. (Creator), Lalezari, J. (Creator), Hassanein, T. (Creator), Martin, P. (Creator), Han, S.-H. (Creator), Dieterich, D. (Creator), Giard, J.-M. (Creator), De La Rosa, G. (Creator), Ahmad, A. (Creator), Luo, E. (Creator), Conery, A. L. (Creator) & Adda, N. (Creator), SAGE Journals, 2022
DOI: 10.25384/sage.c.6301764.v1, https://sage.figshare.com/collections/EDP-514_in_healthy_subjects_and_nucleos_t_ide_reverse_transcriptase_inhibitor-suppressed_patients_with_chronic_hepatitis_B/6301764/1
Dataset